Altimmune(US:ALT) Prnewswireยท2025-08-15 01:32Group 1 - A class action has been filed on behalf of investors who purchased Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023, and June 25, 2025 [1] - Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1] - The allegations state that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial, which failed to achieve statistical significance due to a higher-than-expected placebo response [2] Group 2 - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price dropped from $7.71 per share to $3.61 per share, a decline of over 53% in one day [2] - Shareholders interested in serving as lead plaintiff must submit their papers by October 6, 2025, and do not need to participate in the case to be eligible for recovery [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4]